Join us for an engaging webinar exploring how advances in target-based drug discovery are transforming the way therapeutics are designed and developed. This webinar will examine innovations in ...

Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Artificial intelligence (AI) deep learning is rapidly transforming the biotechnology and pharmaceutical industries. New AI models based on ChatGPT-like algorithms are emerging in many industry ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for treating glioblastoma, a lethal brain tumor. This approach enabled them to ...

Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...